Intrexon (NYSE: XON) and Icon (NASDAQ:ICLR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
This table compares Intrexon and Icon’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Intrexon has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Icon has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Earnings and Valuation
This table compares Intrexon and Icon’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intrexon||$230.98 million||9.29||-$117.01 million||($0.92)||-18.04|
|Icon||$1.76 billion||4.18||$281.48 million||$5.39||25.19|
Icon has higher revenue and earnings than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Intrexon and Icon, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intrexon presently has a consensus target price of $34.67, suggesting a potential upside of 108.84%. Icon has a consensus target price of $127.20, suggesting a potential downside of 6.33%. Given Intrexon’s higher probable upside, analysts clearly believe Intrexon is more favorable than Icon.
Institutional & Insider Ownership
83.6% of Intrexon shares are held by institutional investors. Comparatively, 87.9% of Icon shares are held by institutional investors. 48.2% of Intrexon shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Icon beats Intrexon on 11 of the 15 factors compared between the two stocks.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.